3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
6
Genitourinary
2
Breast
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
5
Breast Neoplasms
3
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Preference
1
Patient Acceptance of Health Care
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Interventions
Gemcitabine
69
Fluorouracil
44
pembrolizumab
43
Oxaliplatin
42
Capecitabine
40
Bevacizumab
37
Leucovorin
36
Irinotecan
31
Cisplatin
27
Nivolumab
24
Paclitaxel
21
Cetuximab
21
Panitumumab
20
130-nm albumin-bound paclitaxel
20
Sorafenib
18
Albumin-Bound Paclitaxel
18
Drug Therapy
15
Docetaxel
15
Cyclophosphamide
15
Radiotherapy
14
Blood Specimen Collection
14
IFL protocol
12
atezolizumab
11
Exercise
11
Taxes
10
budigalimab
9
Erlotinib Hydrochloride
9
trametinib
8
Folfox protocol
8
Carboplatin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Focus Groups
×
Gastrointestinal
×
Clear all
NCT06236373
2024-12-09
Survivorship
University of Modena and Reggio Emilia
Recruiting
45 enrolled